Long COVID is the chronic manifestation of lasting symptoms of SARS-CoV-2 infection that can last for at least 3 months, with shortness of breath and system inefficiency often remaining central issues for many patients.
On March 11, 2020, the World Health Organization officially declared the COVID pandemic, following reports of more than 118,000 cases in 114 countries and a 3.6% mortality rate.1 In the 5 years since, much has been investigated, analyzed, and learned about how the SARS-CoV-2 virus inflicts damage on the human body and its intertwined systems—in particular, the cardiovascular, or circulatory, and respiratory systems—and the impact of Long COVID.
Long COVID is the chronic manifestation of symptoms of SARS-CoV-2 infection that can last for at least 3 months—and these symptoms can simply persist or either improve or worsen.2 One of the symptoms that remains a central issue for many patients with Long COVID is shortness of breath, which is often triggered by high levels of activity but can be influenced by many factors, including muscle efficiency, anxiety, and cardiovascular function.
In this interview, Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of Pulmonary Wellness and Rehabilitation Center in New York City, discusses how pulmonary and cardiovascular insufficiency manifest in patients who have sustained lung damage—from a bout with COVID or otherwise—and the impact this can have on their daily and overall quality of life.
“When people start to get short of breath—and it doesn't matter what your symptom is; it could be shortness of breath, it could be chest pain, it could be back pain or hip pain or knee pain—when people start to become uncomfortable doing an activity, they find ways to avoid that activity,” he explains. “And particularly as it relates to shortness of breath, when people stop those activities, their body deconditions and they work less efficiently. All the muscles that you use to walk up the stairs, all the systems that you use to walk up the stairs or walk up a hill, become less efficient.”
References
1. AJMC staff. A timeline of COVID-19 developments in 2020. AJMC®. January 1, 2021. Accessed February 25, 2025. https://www.ajmc.com/view/a-timeline-of-covid19-developments-in-2020
2. Long COVID basics. CDC. February 3, 2025. Accessed February 25, 2025. https://www.cdc.gov/covid/long-term-effects/index.html
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More